June 1, 2015New England Journal of Medicine1,601 citationsOpen Access
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with hormone-receptor-positive metastatic breast cancer who had progression of disease during prior endocrine therapy, palbociclib combined with fulvestrant resulted in longer progression-free survival than fulvestrant alone. (Funded by Pfizer; PALOMA3 ClinicalTrials.gov number, NCT01942135.).